Investigational drugs in development for focal segmental glomerulosclerosis.

@article{Trachtman2017InvestigationalDI,
  title={Investigational drugs in development for focal segmental glomerulosclerosis.},
  author={Howard A. Trachtman},
  journal={Expert opinion on investigational drugs},
  year={2017},
  volume={26 8},
  pages={945-952}
}
INTRODUCTION Focal segmental glomerulosclerosis is an important cause of end stage kidney disease and is a paradigm for the study of glomerular scarring. There are no FDA approved treatments for this condition. Current therapies, assessed based on reduction in proteinuria, are generally effective in a subset of patients which suggests that FSGS is a… CONTINUE READING